
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a securities purchase agreement […]